NewsPronto

 
Times Advertising


.

ACN Newswire

Read more press releases from ACN Newswire here

U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for Treatment of Insomnia in Adult Patients

  • Written by ACN Newswire

image

TOKYO, Dec 23, 2019 - (JCN Newswire) - Eisai Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for its in-house discovered and developed orexin receptor antagonist DAYVIGOTM (lemborexant). DAYVIGO was approved for the treatment of insomnia characterized by difficulties with sleep onset...

Read more: U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for Treatment of Insomnia in Adult Patients